From Code to Cure — How Gene Editing Is Rewriting Medicine
The numbers shaping the genomics revolution
CRISPR just cured sickle cell disease — the first gene-editing therapy is here
The FDA approved Casgevy (CRISPR Therapeutics / Vertex) as the first-ever gene-editing therapy for sickle cell disease and beta-thalassemia. A single infusion edits a patient's own stem cells, potentially curing lifelong genetic diseases.
The Human Genome Project cost $100 million per genome in 2001. Today Illumina's NovaSeq X delivers a whole genome for ~$200. That's a 500,000x cost reduction — faster than Moore's Law — unlocking population-scale genomics.
AI + genomics = drug discovery in months, not decades
The biggest drug class in history started with a gene
Genomics identified GLP-1 receptor biology decades ago. That foundational genetic research led to the creation of GLP-1 receptor agonists — drugs that mimic a natural hormone to regulate blood sugar and appetite. What started as a diabetes treatment became the most transformative drug class in pharmaceutical history, now treating obesity, cardiovascular disease, and potentially Alzheimer's and NASH.
The biggest drug class in history started with a gene.
Sources: Company earnings reports, FDA, ClinicalTrials.gov
First-mover in CRISPR therapeutics with FDA-approved product. Casgevy addresses sickle cell disease (~100K US patients) and beta-thalassemia. In vivo CRISPR programs could unlock liver diseases, autoimmune conditions, and diabetes — far larger addressable markets. Vertex partnership provides commercialization muscle. CRISPR platform is a one-time cure model, not chronic treatment.
Casgevy adoption is slow — $2M per patient creates payer pushback. Treatment requires myeloablative conditioning (harsh chemotherapy prep). Ex vivo manufacturing is complex and capacity-constrained. Cash burn continues with in vivo programs years from revenue. Competition from base editing (Beam) and prime editing (Prime Medicine) could leapfrog CRISPR-Cas9.
The companies building the tools and therapies of the genomics revolution
Edit genes directly inside the body — no cell extraction, one infusion, permanent cure
First company to demonstrate in vivo CRISPR gene editing in humans. Phase 3 HAELO trial for ATTR amyloidosis — a single infusion that permanently edits liver cells to stop producing toxic protein. If successful, this is a one-time cure replacing lifelong treatment. Pipeline: hereditary angioedema, hemophilia.
Base editing makes single-letter DNA changes without cutting the double helix — reducing off-target risks vs. CRISPR-Cas9. Beam's lead programs target sickle cell disease and T-cell acute lymphoblastic leukemia. If base editing proves safer than standard CRISPR, it could become the preferred editing modality for most genetic diseases.
Prime editing can make any type of DNA edit — insertions, deletions, all 12 point mutations — without double-strand breaks. Think of it as "search-and-replace" for the genome. Prime Medicine is advancing programs in chronic granulomatous disease and alpha-1 antitrypsin deficiency. The most versatile editing technology, still early-stage.
Artificial intelligence is compressing decades of drug discovery into months
DeepMind's AlphaFold predicted the 3D structure of 200M+ proteins — nearly every known protein in existence. This open-sourced database gave every drug company on Earth a structural roadmap for designing targeted therapies. Before AlphaFold, determining a single protein structure took months; now it takes seconds.
Traditional drug discovery: 10-15 years and $2.6B per approved drug. AI-driven genomics is compressing this to 2-3 years in early stages. AI identifies drug targets from genomic data, predicts molecular interactions, optimizes lead compounds, and matches patients to clinical trials — all at machine speed.
AI-powered patient matching reduces trial enrollment time by 30-50%. Genomic biomarkers enable enriched trial populations — patients more likely to respond. This means smaller, faster, cheaper trials with higher success rates. RXRX and Isomorphic Labs (Google DeepMind) are leading this convergence.
Recursion Pharmaceuticals has built 2.3 petabytes of biological data and trained AI on 5B+ experiments. Isomorphic Labs (spun out of DeepMind) is applying AlphaFold-class models directly to drug design. These two represent the frontier of AI-native drug discovery — where the lab is digital-first.
Positioning all tickers by risk and reward potential
The headwinds and hurdles facing the genomics revolution
At $2.2M per treatment, Casgevy faces severe payer pushback. Insurance coverage is uncertain for many patients. The complex ex vivo manufacturing process requires specialized treatment centers, limiting geographic reach. First-year revenue of $116M fell below bullish estimates.
Gene therapy faces heightened FDA scrutiny after durability concerns in earlier therapies. Long-term safety monitoring requirements extend timelines and costs. The evolving regulatory framework for in vivo CRISPR adds uncertainty. Each new editing modality (base, prime) requires its own safety validation.
Gene therapy manufacturing is extraordinarily complex — viral vectors, cell processing, quality control. Production yields are low and costs are high. Scaling from hundreds to thousands of patients requires massive infrastructure investment. Manufacturing failures have derailed multiple gene therapy programs.
CRISPR Therapeutics and Intellia are burning through cash with in vivo programs years from revenue. CRSP has ~$1.8B cash but Casgevy ramp is slow. NTLA is pre-revenue with Phase 3 trials still enrolling. Dilution risk is real if gene therapy commercialization timelines extend further than expected.
Chinese biotech companies are developing biosimilar versions of blockbuster drugs at a fraction of the cost. WuXi Biologics and Henlius are already shipping to emerging markets. Potential IP challenges in gene therapy as Chinese firms develop CRISPR-based therapies. Pricing pressure could compress margins globally.
CRISPR-Cas9 can make unintended edits elsewhere in the genome. While no serious adverse events have occurred in trials, long-term monitoring is required. Off-target effects could surface years after treatment — a risk unique to permanent gene editing. This uncertainty weighs on valuation multiples for pure-play CRISPR stocks.
Key inflection points from 2026 to 2035